Reeves C, Miura SST, Chappell AR, Banaag A, Coles. Trends in influenza vaccination uptake in a universally insured population in the united states, 2017-2023. Vaccine. 2025 Dec 3;71:128052
Background: Annual vaccination against seasonal influenza is recommended for all persons ages ≥6 months in the U.S., as it is effective in reducing influenza-related illness and death. However, data show that only 44% of U.S. adults were vaccinated in the 2024-25 season. Previous research indicates that low vaccination uptake is linked to sociodemographic characteristics, region and health insurance status. We assessed trends in influenza vaccination coverage between 2017-18 and 2022-23 seasons and evaluated factors associated with uptake in U.S. Military Health System (MHS) beneficiaries during the 2022-2023 influenza season.
Methods: We performed a cross-sectional study using all eligible beneficiaries ages 1-64 years between July 2017 and March 2023. We used chi-square tests to compare vaccination rates between the first and last season and multivariable logistic regression to assess factors associated with vaccination coverage in the 2022-23 season.
Results: We identified 6,006,857 eligible MHS beneficiaries over the six influenza seasons. Vaccination rates between the first and last influenza season increased from 33% to 36.5% (p-value < 0.0001). We observed significant decreases in vaccination rates over the study period among ages 5-17, dependent beneficiaries, and those in the Northeastern U.S. In 2022-23, female beneficiaries were more likely to be vaccinated than males (aOR 1.33, p-value < 0.0001). In addition, Black, Hispanic, and Asian/Pacific Islander beneficiaries had marginally higher rates of coverage as compared to White beneficiaries (aOR: 1.07, 1.10, 1.18, p-value < 0.0001).
Conclusions: Our results indicate that overall influenza vaccination rates increased between 2017 and 2023, however, use of the EHR systems alone for tracking vaccination data tends to underestimate coverage in the MHS. Tailored strategies are needed to improve influenza vaccination uptake to prevent illness, hospitalization and death.
Methods: We performed a cross-sectional study using all eligible beneficiaries ages 1-64 years between July 2017 and March 2023. We used chi-square tests to compare vaccination rates between the first and last season and multivariable logistic regression to assess factors associated with vaccination coverage in the 2022-23 season.
Results: We identified 6,006,857 eligible MHS beneficiaries over the six influenza seasons. Vaccination rates between the first and last influenza season increased from 33% to 36.5% (p-value < 0.0001). We observed significant decreases in vaccination rates over the study period among ages 5-17, dependent beneficiaries, and those in the Northeastern U.S. In 2022-23, female beneficiaries were more likely to be vaccinated than males (aOR 1.33, p-value < 0.0001). In addition, Black, Hispanic, and Asian/Pacific Islander beneficiaries had marginally higher rates of coverage as compared to White beneficiaries (aOR: 1.07, 1.10, 1.18, p-value < 0.0001).
Conclusions: Our results indicate that overall influenza vaccination rates increased between 2017 and 2023, however, use of the EHR systems alone for tracking vaccination data tends to underestimate coverage in the MHS. Tailored strategies are needed to improve influenza vaccination uptake to prevent illness, hospitalization and death.
See Also:
Latest articles in those days:
- Genetically distinct H5N2 high pathogenicity avian influenza virus isolated from a peregrine falcon on Amami-Oshima Island, Japan, harboring enhanced pathogenicity-associated amino acids in the PA pro 3 hours ago
- Development of a dually-amplified analytical method for rapid, specific and ultrasensitive detection of avian influenza virus H5N1 DNA 3 hours ago
- Can H5N1 avian influenza in dairy cattle be contained in the US? 3 hours ago
- Immune history confers antibody- and T cell-dependent cross-protection against highly pathogenic avian influenza H5N1 viruses 3 hours ago
- An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins 3 hours ago
[Go Top] [Close Window]


